Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director · CEO and Chairman of the Board | September 05, 2019 | September 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date September 05, 2019 · Filed September 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,000 |
Ending reported balance
After 2019-09-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-09-05 · Purchase · Acquired 10,000 · Balance 105,000 Row 2 · 2019-09-06 · Purchase · Acquired 5,500 · Balance 110,500 Row 3 · 2019-09-06 · Purchase · Acquired 2,500 · Balance 113,000 Row 4 · 2019-09-06 · Purchase · Acquired 4,000 · Balance 117,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2020-12-14 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2022-02-09 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 50,000 F1: The option is exercisable to the extent of 16,667 shares on each of February 10, 2012 and February 10, 2013 and 16,666 shares on February 10, 2014. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2022-12-07 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 20,000 F2: The option is exercisable to the extent of 10,000 shares on each of December 7, 2012 and December 7, 2013. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2023-10-04 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 12,500 F3: The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2024-02-18 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 50,000 F4: The option is exercisable to the extent of 16,667 shares on each of February 18, 2014 and February 18, 2015 and 16,666 shares on February 18, 2016. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2024-10-23 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 150,000 F5: The option is exercisable to the extent of 50,000 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2025-09-04 | Direct | 208,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 208,000 F6: The option is exercisable to the extent of 104,000 shares on December 22, 2015, 34,667 shares on each of September 4, 2016 and September 4, 2017, and 34,666 shares on September 4, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2026-06-10 | Direct | 275,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 275,000 F7: The option is exercisable to the extent of 91,667 shares on each of June 10, 2016 and June 10, 2017, and 91,666 shares on June 10, 2018. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2027-06-23 | Direct | 275,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 275,000 F8: The option is exercisable to the extent of 91,667 shares on each of June 23, 2017 and June 23, 2018, and 91,666 shares on June 23, 2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2028-10-29 | Direct | 275,000 |
Reported balance
Holding disclosure · report date 2019-09-05 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 275,000 F9: The option is exercisable to the extent of 91,667 shares on each of October 29, 2018 and October 29, 2019, and 91,666 shares on October 29, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is exercisable to the extent of 16,667 shares on each of February 10, 2012 and February 10, 2013 and 16,666 shares on February 10, 2014.
F2: The option is exercisable to the extent of 10,000 shares on each of December 7, 2012 and December 7, 2013.
F3: The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014.
F4: The option is exercisable to the extent of 16,667 shares on each of February 18, 2014 and February 18, 2015 and 16,666 shares on February 18, 2016.
F5: The option is exercisable to the extent of 50,000 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017.
F6: The option is exercisable to the extent of 104,000 shares on December 22, 2015, 34,667 shares on each of September 4, 2016 and September 4, 2017, and 34,666 shares on September 4, 2018.
F7: The option is exercisable to the extent of 91,667 shares on each of June 10, 2016 and June 10, 2017, and 91,666 shares on June 10, 2018.
F8: The option is exercisable to the extent of 91,667 shares on each of June 23, 2017 and June 23, 2018, and 91,666 shares on June 23, 2019.
F9: The option is exercisable to the extent of 91,667 shares on each of October 29, 2018 and October 29, 2019, and 91,666 shares on October 29, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2019 Filed Sep 6, 2019 21:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 4,000 | $0.23 | $920.00 |
DisclosureSEC source: 0001567619-19-018004 · doc1.xml · nonDerivative · entry 4 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,000 Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 21:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.24 | $591.25 |
DisclosureSEC source: 0001567619-19-018004 · doc1.xml · nonDerivative · entry 3 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 21:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 5,500 | $0.24 | $1,320.00 |
DisclosureSEC source: 0001567619-19-018004 · doc1.xml · nonDerivative · entry 2 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,500 Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 21:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 10,000 | $0.27 | $2,699.00 |
DisclosureSEC source: 0001567619-19-018004 · doc1.xml · nonDerivative · entry 1 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 20:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.27 | $675.00 |
DisclosureSEC source: 0001567619-19-017673 · doc1.xml · nonDerivative · entry 4 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 20:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.26 | $657.50 |
DisclosureSEC source: 0001567619-19-017673 · doc1.xml · nonDerivative · entry 3 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Read SEC document |
| August 27, 2019 Filed Aug 29, 2019 20:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.26 | $650.00 |
DisclosureSEC source: 0001567619-19-017673 · doc1.xml · nonDerivative · entry 2 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Read SEC document |
| August 27, 2019 Filed Aug 29, 2019 20:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.25 | $625.00 |
DisclosureSEC source: 0001567619-19-017673 · doc1.xml · nonDerivative · entry 1 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:36 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,000 | $0.24 | $480.00 |
DisclosureSEC source: 0001567619-19-017526 · doc1.xml · nonDerivative · entry 3 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:36 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,300 | $0.26 | $339.30 |
DisclosureSEC source: 0001567619-19-017526 · doc1.xml · nonDerivative · entry 2 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:36 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,700 | $0.29 | $493.00 |
DisclosureSEC source: 0001567619-19-017526 · doc1.xml · nonDerivative · entry 1 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,700 Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 275,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 21 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-10-29 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of October 29, 2018 and October 29, 2019, and 91,666 shares on October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 275,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 20 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,000 shares Expires 2028-10-29 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of October 29, 2018 and October 29, 2019, and 91,666 shares on October 29, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 275,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 19 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2027-06-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of June 23, 2017 and June 23, 2018, and 91,666 shares on June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 275,000 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 18 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,000 shares Expires 2027-06-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F8 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of June 23, 2017 and June 23, 2018, and 91,666 shares on June 23, 2019. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 275,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 17 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2026-06-10 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of June 10, 2016 and June 10, 2017, and 91,666 shares on June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 275,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 16 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,000 shares Expires 2026-06-10 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of June 10, 2016 and June 10, 2017, and 91,666 shares on June 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 208,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 15 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,000 Underlying: Common Stock · 208,000 shares Expires 2025-09-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 104,000 shares on December 22, 2015, 34,667 shares on each of September 4, 2016 and September 4, 2017, and 34,666 shares on September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 208,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 14 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 208,000 shares Expires 2025-09-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 104,000 shares on December 22, 2015, 34,667 shares on each of September 4, 2016 and September 4, 2017, and 34,666 shares on September 4, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 150,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 13 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-10-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 50,000 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 150,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 12 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2024-10-23 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 50,000 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 11 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-02-18 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 18, 2014 and February 18, 2015 and 16,666 shares on February 18, 2016. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 50,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 10 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-02-18 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 18, 2014 and February 18, 2015 and 16,666 shares on February 18, 2016. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 12,500 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 9 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2023-10-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 12,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 8 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2023-10-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 20,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 7 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-12-07 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 20,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 6 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-12-07 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 5 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-02-09 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 10, 2012 and February 10, 2013 and 16,666 shares on February 10, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 50,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 4 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-02-09 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 10, 2012 and February 10, 2013 and 16,666 shares on February 10, 2014. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 3 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:21 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007663 · doc1.xml · derivative · entry 2 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:51 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 275,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001567619-18-004791 · doc1.xml · derivative · entry 11 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-10-29 F9 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of October 29, 2018 and October 29, 2019, and 91,666 shares on October 29, 2020. Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 20:59 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 275,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-17-026104 · doc1.xml · derivative · entry 10 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2027-06-23 F8 · derivative.exercise_date: The option is exercisable to the extent of 91,667 shares on each of June 23, 2017 and June 23, 2018, and 91,666 shares on June 23, 2019. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 208,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 16 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,000 Underlying: Common Stock · 208,000 shares Expires 2025-09-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 104,000 shares on December 22, 2015, 34,667 shares on each of September 4, 2016 and September 4, 2017, and 34,666 shares on September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 208,000 | Not disclosed Strike: $7.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 15 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 208,000 shares Expires 2025-09-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F7 · derivative.exercise_date: The option is exercisable to the extent of 104,000 shares on December 22, 2015, 34,667 shares on each of September 4, 2016 and September 4, 2017, and 34,666 shares on September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 150,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 14 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-10-23 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 50,000 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 150,000 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 13 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2024-10-23 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F6 · derivative.exercise_date: The option is exercisable to the extent of 50,000 shares on each of October 23, 2015, October 23, 2016 and October 23, 2017. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 12 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-02-18 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 18, 2014 and February 18, 2015 and 16,666 shares on February 18, 2016. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 50,000 | Not disclosed Strike: $13.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 11 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-02-18 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F5 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 18, 2014 and February 18, 2015 and 16,666 shares on February 18, 2016. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 12,500 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 10 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2023-10-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 12,500 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 9 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2023-10-04 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 20,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 8 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-12-07 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 20,000 | Not disclosed Strike: $30.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 7 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-12-07 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 10,000 shares on each of December 7, 2012 and December 7, 2013. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 6 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-02-09 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 10, 2012 and February 10, 2013 and 16,666 shares on February 10, 2014. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 50,000 | Not disclosed Strike: $21.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 5 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-02-09 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of February 10, 2012 and February 10, 2013 and 16,666 shares on February 10, 2014. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 4,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 4 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| February 14, 2017 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · derivative · entry 3 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2020-12-14 F9 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. Read SEC document |
| September 02, 2016 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GiftCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · nonDerivative · entry 2 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F1 · price: Gift to family member. Read SEC document |
| August 08, 2016 Filed Feb 14, 2017 20:31 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GiftCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-007158 · doc1.xml · nonDerivative · entry 1 Weinreb Mark · CIK 0001527212 · Director · CEO and Chairman of the Board · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 F1 · price: Gift to family member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.